ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Key facts

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.

Intervention

ICP-248(drug)

Enrollment

226 enrolled

Eligibility

18-80 years · All sexes

Timeline

2024 – 2031

Study locations (30)

• The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
• Anhui Provincial Hospital (The First Affiliated Hospital of University of Science and Technology of China), Hefei, Anhui, China
• The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
• Peking University Third Hospital, Beijing, Beijing Municipality, China
• The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• Xinqiao Hospital, the Second Affiliated Hospital of Army Military Medical University, Chongqing, Chongqing Municipality, China
• Fujian Medical University Union Hospital, Fuzhou, Fujian, China
• The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
• Gansu Provincial People's Hospital, Lanzhou, Gansu, China
• Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
• Guangdong General Hospital, Guangzhou, Guangdong, China
• Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
• The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
• The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07194980
  Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Fred Hutchinson Cancer Center
• RECRUITINGEARLY PHASE1NCT07428707
  Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
  National Heart, Lung, and Blood Institute (NHLBI)
• RECRUITINGPHASE4NCT07218341
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Eli Lilly and Company
• RECRUITINGPHASE1NCT06859008
  Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07271667
  A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
  Curis, Inc.
• RECRUITINGPHASE2NCT07014917
  Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
  Zulfa Omer
• RECRUITINGPHASE2NCT06958705
  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE1, PHASE2NCT07052695
  Mosunetuzumab for CLL MRD Clearance
  Inhye Ahn

See all trials for B-cell chronic lymphocytic leukemia →